, Satoshi Asai1
, Kenji Matsuo1
, Takumi Sugihara1
, Kensei Kawasaki1
, Aoi Koizumi1
, Sayuri Hashimoto1
, Kaho Takagi1
, Yoshihiro Shima1
, Tomoya Hashimura1
, Kento Hisamatsu1
, Yuma Fujita1
, Yuichiro Hamamoto2
, Shuta Otachi1
, Yuki Kano1
, Eisuke Nakao1
, Eisuke Akamine1
, Yoshinobu Hirose2
1Department of Gastroenterology, Tane General Hospital, Osaka City, Japan
2Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
The authors have no potential conflicts of interest.
Funding
None.
Acknowledgments
We would like to express our sincere gratitude to all the medical staff at Tane General Hospital who were involved in this study.
Author Contributions
Conceptualization: KoT; Data curation: KoT, KM; Formal analysis: TS, KK; Investigation: AK, SH; Methodology: KaT, YS; Project administration: YS, TH, KH; Resources: SO, YK; Supervision: SA, EN, EA, YHi; Validation: YHa, YHi; Visualization: KoT; Writing–original draft: KoT; Writing–review & editing: all authors.
Values are presented as median (interquartile range) or number (%).
EUS-TA, endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion (Acquire, Franseen-tip needle; Boston Scientific); TopGain (Franseen-tip needle, Medi-Globe; Achenmuhle); Trident (tri-tip-shaped, Micro-Tech); subepithelial lesion; FNB, fine-needle biopsy; MIAB, mucosal incision-assisted biopsy.
| Clinical outcomes | EUS-TA with HEP 1p1a | EUS-TA with HEP non-1p1a (n=18) | p-value (1p1a vs. non-1p1a) | |||
|---|---|---|---|---|---|---|
| All patients (n=36) | Patients with SELs ≥20 mm (n=24) | Patients with SELs <20 mm (n=12) | p-value (≥20 vs. <20 mm) | |||
| Technical success | 36 (100.0) | 24 (100.0) | 12 (100.0) | NA | 18 (100.0) | NA |
| Success of pathological differentiation between benign and malignant | 34 (94.4) | 24 (100.0) | 10 (83.3) | 0.11 | 16 (88.9) | 0.59 |
| Success of immunohistochemistrya) | 25/28 (89.3) | 18/19 (94.7) | 7/9 (77.8) | 0.23 | 8/10 (80.0) | 0.59 |
| Success of definitive histologic diagnosis | 31 (86.1) | 23 (95.8) | 8 (66.7) | 0.03 | 15 (83.3) | 1 |
| Adverse events | 0 (0) | 0 (0) | 0 (0) | NA | 0 (0) | NA |
Values are presented as number (%) or number/total number (%).
EUS-TA, Endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion; NA, not applicable.
a)Immunohistochemistry was planned only when the pathologist deemed it necessary for establishing the definitive histologic diagnosis.
| Case | Failure of | Age (yr) | Sex | Target organ | Diameter of SELs | Type of needle | Diameter of needle | Session | Additional examination | Final diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|
| 1a) | Differentiation | 48 | Male | Duodenum | 15 | Acquire | 22 | 6 | MIAB | Lipoma |
| 2b) | Differentiation | 83 | Female | Stomach | 15 | TopGain | 19 | 4 | None | Indefinite diagnosis |
| 3c) | Immunohistochemistry | 78 | Female | Stomach | 8 | Acquire | 25 | 3 | None | GIST |
| 4c) | Immunohistochemistry | 74 | Female | Stomach | 25 | TopGain | 22 | 2 | None | GIST |
| 5d) | Immunohistochemistry | 37 | Female | Esophagus | 13 | Acquire | 19 | 6 | None | Leiomyoma |
SEL, subepithelial lesion; MIAB, mucosal incision-assisted biopsy; GIST, gastrointestinal stromal tumor.
a)In case 1, sufficient specimens were not acquired by endoscopic ultrasound-guided tissue acquisition (EUS-TA); MIAB was alternatively performed.
b)In case 2, sufficient specimens were not acquired using EUS-TA. Observations were performed for >2 years without progression.
c)In cases 3 and 4, surgical resection was performed without additional tissue acquisition because GISTs were highly suspected based on standard hematoxylin and eosin staining.
d)In case 5, leiomyoma was strongly suspected without immunohistochemistry, and observation was performed for 5 years without progression.
| Characteristic | EUS-TA with HEP 1p1a | EUS-TA with HEP non-1p1a (n=18) | p-value (1p1a vs. non-1p1a) | |||
|---|---|---|---|---|---|---|
| All patients (n=36) | Patients with SELs ≥20 mm (n=24) | Patients with SELs <20 mm (n=12) | p-value (≥20 vs. <20 mm) | |||
| Age (yr) | 66 (51.8–76.3) | 69 (54.8–76.3) | 56.5 (50.3–66.5) | 0.25 | 59.5 (54.3–74.8) | 0.66 |
| Sex, male | 20 (55.6) | 15 (62.5) | 5 (41.7) | 0.30 | 8 (44.4) | 0.57 |
| Target organs | 0.29 | 0.86 | ||||
| Esophagus | 5 (13.9) | 2 (8.3) | 3 (25.0) | 2 (11.1) | ||
| Stomach | 24 (66.7) | 18 (75.0) | 6 (50.0) | 12 (66.7) | ||
| Duodenum | 7 (19.4) | 4 (16.7) | 3 (25.0) | 4 (22.2) | ||
| Lesion diameter (mm) | 20.5 (15–31.3) | 30 (20.8–35.5) | 13.5 (12.0–15.0) | <0.001 | 15 (13.5–20.0) | 0.02 |
| Needle types | 0.32 | 0.13 | ||||
| Acquire | 16 (44.4) | 9 (37.5) | 7 (58.3) | 8 (44.4) | ||
| TopGain | 12 (33.3) | 10 (41.7) | 2 (16.7) | 2 (11.1) | ||
| Trident | 8 (22.2) | 5 (20.8) | 3 (25.0) | 8 (44.4) | ||
| Needle gauge | 0.03 | 0.79 | ||||
| FNB 19-G | 15 (41.7) | 13 (54.2) | 2 (16.7) | 6 (33.3) | ||
| FNB 22-G | 20 (55.6) | 11 (45.8) | 9 (75.0) | 11 (61.1) | ||
| FNB 25-G | 1 (2.8) | 0 | 1 (8.3) | 1 (5.6) | ||
| No. of passes | 3 (2–4) | 3 (2–4) | 3 (3.0–4.5) | 0.32 | 3.5 (2.3–4.0) | 0.95 |
| Physician, expert | 23 (63.9) | 16 (66.7) | 7 (58.3) | 0.72 | 9 (50.0) | 1 |
| MIAB | 1 (2.8) | 0 (0) | 1 (8.3) | 0.33 | 2 (11.1) | 0.26 |
| Clinical outcomes | EUS-TA with HEP 1p1a | EUS-TA with HEP non-1p1a (n=18) | p-value (1p1a vs. non-1p1a) | |||
|---|---|---|---|---|---|---|
| All patients (n=36) | Patients with SELs ≥20 mm (n=24) | Patients with SELs <20 mm (n=12) | p-value (≥20 vs. <20 mm) | |||
| Technical success | 36 (100.0) | 24 (100.0) | 12 (100.0) | NA | 18 (100.0) | NA |
| Success of pathological differentiation between benign and malignant | 34 (94.4) | 24 (100.0) | 10 (83.3) | 0.11 | 16 (88.9) | 0.59 |
| Success of immunohistochemistry |
25/28 (89.3) | 18/19 (94.7) | 7/9 (77.8) | 0.23 | 8/10 (80.0) | 0.59 |
| Success of definitive histologic diagnosis | 31 (86.1) | 23 (95.8) | 8 (66.7) | 0.03 | 15 (83.3) | 1 |
| Adverse events | 0 (0) | 0 (0) | 0 (0) | NA | 0 (0) | NA |
| Clinical outcomes | EUS-TA with HEP 1p1a | EUS-TA with HEP non-1p1a (n=18) | p-value (1p1a vs. non-1p1a) | |||
|---|---|---|---|---|---|---|
| All patients (n=36) | Patients with SELs ≥20 mm (n=24) | Patients with SELs <20 mm (n=12) | p-value (≥20 vs. <20 mm) | |||
| Tissue integrity score | 1.92±0.37) | 2.0±0 | 1.75±0.62 | 0.054 | 1.83±0.51 | 0.50 |
| Cellularity score | 1.83±0.51 | 1.96±0.20 | 1.58±0.79 | 0.034 | 1.94±0.24 | 0.38 |
| Maximum length of white sequential specimen (μm) | 3,850 (1,757.5–5,250) | 4,000 (2,375–6,250) | 1,845 (1,207.5–3,775) | 0.031 | 2,705 (1,072.5–3,335) | 0.081 |
| Final diagnosis | EUS-TA with HEP 1p1a | EUS-TA with HEP non-1p1a (n=18) | ||
|---|---|---|---|---|
| All patients (n=36) | Patients with SELs ≥20 mm (n=24) | Patients with SELs <20 mm (n=12) | ||
| GIST | 21 (58.3) | 16 (66.7) | 5 (41.7) | 6 (33.3) |
| Adenocarcinoma | 3 (8.3) | 3 (12.5) | 0 (0) | 2 (11.1) |
| Squamous cell carcinoma | 2 (5.6) | 1 (4.2) | 1 (8.3) | 0 (0) |
| Malignant lymphoma | 1 (2.8) | 1 (4.2) | 0 (0) | 1 (5.6) |
| Benign subepithelial lesion | 9 (25.0) | 2 (8.3) | 7 (58.3) | 9 (50.0) |
| Leiomyoma | 3 (8.3) | 1 (4.2) | 2 (16.7) | 3 (16.7) |
| Ectopic pancreas | 2 (5.6) | 1 (4.2) | 1 (8.3) | 1 (5.6) |
| Lipoma | 1 (2.8) | 0 (0) | 1 (8.3) | 1 (5.6) |
| Neurofibroma | 1 (2.8) | 0 (0) | 1 (8.3) | 0 (0) |
| Schwannoma | 1 (2.8) | 0 (0) | 1 (8.3) | 0 (0) |
| Brunner’s gland hyperplasia | 0 (0) | 0 (0) | 0 (0) | 2 (11.1) |
| Gastric ulcer | 0 (0) | 0 (0) | 0 (0) | 1 (5.6) |
| Benign tumor without a definitive pathological diagnosis | 1 (2.8) | 0 (0) | 1 (8.3) | 1 (5.6) |
| Case | Failure of | Age (yr) | Sex | Target organ | Diameter of SELs | Type of needle | Diameter of needle | Session | Additional examination | Final diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
Differentiation | 48 | Male | Duodenum | 15 | Acquire | 22 | 6 | MIAB | Lipoma |
| 2 |
Differentiation | 83 | Female | Stomach | 15 | TopGain | 19 | 4 | None | Indefinite diagnosis |
| 3 |
Immunohistochemistry | 78 | Female | Stomach | 8 | Acquire | 25 | 3 | None | GIST |
| 4 |
Immunohistochemistry | 74 | Female | Stomach | 25 | TopGain | 22 | 2 | None | GIST |
| 5 |
Immunohistochemistry | 37 | Female | Esophagus | 13 | Acquire | 19 | 6 | None | Leiomyoma |
Values are presented as median (interquartile range) or number (%). EUS-TA, endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion (Acquire, Franseen-tip needle; Boston Scientific); TopGain (Franseen-tip needle, Medi-Globe; Achenmuhle); Trident (tri-tip-shaped, Micro-Tech); subepithelial lesion; FNB, fine-needle biopsy; MIAB, mucosal incision-assisted biopsy.
Values are presented as number (%) or number/total number (%). EUS-TA, Endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion; NA, not applicable. Immunohistochemistry was planned only when the pathologist deemed it necessary for establishing the definitive histologic diagnosis.
Values are presented as mean±standard deviation or median (interquartile range). EUS-TA, Endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion.
Values are presented as number (%). EUS-TA, Endoscopic ultrasound-guided tissue acquisition; HEP, heparinized wet suction; 1p1a, single-pass single-needle actuation; SEL, subepithelial lesion; GIST, gastrointestinal stromal tumor.
SEL, subepithelial lesion; MIAB, mucosal incision-assisted biopsy; GIST, gastrointestinal stromal tumor. In case 1, sufficient specimens were not acquired by endoscopic ultrasound-guided tissue acquisition (EUS-TA); MIAB was alternatively performed. In case 2, sufficient specimens were not acquired using EUS-TA. Observations were performed for >2 years without progression. In cases 3 and 4, surgical resection was performed without additional tissue acquisition because GISTs were highly suspected based on standard hematoxylin and eosin staining. In case 5, leiomyoma was strongly suspected without immunohistochemistry, and observation was performed for 5 years without progression.
